Luye Pharma Group Ltd. (LYPHF)
OTHER OTC:LYPHF
Want to see LYPHF full AI Analyst Report?
Total Valuation
Luye Pharma Group has a market cap or net worth of $1.28B. The enterprise value is $13.83B.
Market Cap$1.28B
Enterprise Value$13.83B
Share Statistics
Luye Pharma Group has 3,994,515,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,994,515,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Luye Pharma Group’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.05%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)3.05%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee1.19M
Profits Per Employee183.42K
Employee Count5,150
Asset Turnover0.19
Inventory Turnover2.18
Valuation Ratios
The current PE Ratio of Luye Pharma Group is 8.3. Luye Pharma Group’s PEG ratio is 1.03.
PE Ratio8.3
PS Ratio1.56
PB Ratio0.60
Price to Fair Value0.60
Price to FCF12.29
Price to Operating Cash Flow25.88
PEG Ratio1.03
Income Statement
In the last 12 months, Luye Pharma Group had revenue of 6.15B and earned 602.73M in profits. Earnings per share was 0.15.
Revenue6.15B
Gross Profit4.05B
Operating Income1.21B
Pretax Income920.19M
Net Income602.73M
EBITDA2.03B
Earnings Per Share (EPS)0.15
Cash Flow
In the last 12 months, operating cash flow was 348.56M and capital expenditures 63.69M, giving a free cash flow of 412.24M billion.
Operating Cash Flow348.56M
Free Cash Flow412.24M
Free Cash Flow per Share0.10
Dividends & Yields
Luye Pharma Group pays an annual dividend of $0.008, resulting in a dividend yield of ―
Dividend Per Share$0.008
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change21.27%
50-Day Moving Average0.36
200-Day Moving Average0.32
Relative Strength Index (RSI)56.16
Average Volume (3m)0.00
Important Dates
Luye Pharma Group upcoming earnings date is Aug 27, 2026, TBA (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateAug 27, 2026
Ex-Dividend Date―
Financial Position
Luye Pharma Group as a current ratio of 1.53, with Debt / Equity ratio of 58.59%
Current Ratio1.53
Quick Ratio1.44
Debt to Market Cap0.98
Net Debt to EBITDA2.43
Interest Coverage Ratio1.81
Taxes
In the past 12 months, Luye Pharma Group has paid 232.79M in taxes.
Income Tax232.79M
Effective Tax Rate0.25
Enterprise Valuation
Luye Pharma Group EV to EBITDA ratio is 7.15, with an EV/FCF ratio of 18.59.
EV to Sales2.36
EV to EBITDA7.15
EV to Free Cash Flow18.59
EV to Operating Cash Flow8.14
Balance Sheet
Luye Pharma Group has $8.88B in cash and marketable securities with $9.42B in debt, giving a net cash position of -$541.73M billion.
Cash & Marketable Securities$8.88B
Total Debt$9.42B
Net Cash-$541.73M
Net Cash Per Share-$0.14
Tangible Book Value Per Share$2.77
Margins
Gross margin is 66.00%, with operating margin of 19.70%, and net profit margin of 9.81%.
Gross Margin66.00%
Operating Margin19.70%
Pretax Margin14.97%
Net Profit Margin9.81%
EBITDA Margin33.01%
EBIT Margin19.70%
Analyst Forecast
The average price target for Luye Pharma Group is $0.55, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$0.55
Price Target Upside37.84% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast4.19%
EPS Growth Forecast27.59%